Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.04
DGX's Cash-to-Debt is ranked lower than
98% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. DGX: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
DGX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.08 Max: 0.44
Current: 0.04
0.02
0.44
Equity-to-Asset 0.47
DGX's Equity-to-Asset is ranked lower than
71% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. DGX: 0.47 )
Ranked among companies with meaningful Equity-to-Asset only.
DGX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3  Med: 0.46 Max: 0.56
Current: 0.47
0.3
0.56
Debt-to-Equity 0.75
DGX's Debt-to-Equity is ranked lower than
74% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. DGX: 0.75 )
Ranked among companies with meaningful Debt-to-Equity only.
DGX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.46  Med: 0.81 Max: 1.41
Current: 0.75
0.46
1.41
Debt-to-EBITDA 2.75
DGX's Debt-to-EBITDA is ranked lower than
64% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. DGX: 2.75 )
Ranked among companies with meaningful Debt-to-EBITDA only.
DGX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.88  Med: 2.43 Max: 3.09
Current: 2.75
1.88
3.09
Interest Coverage 6.54
DGX's Interest Coverage is ranked lower than
71% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. DGX: 6.54 )
Ranked among companies with meaningful Interest Coverage only.
DGX' s Interest Coverage Range Over the Past 10 Years
Min: 5.74  Med: 7.04 Max: 9.27
Current: 6.54
5.74
9.27
Piotroski F-Score: 5
Altman Z-Score: 3.21
Beneish M-Score: -2.49
WACC vs ROIC
7.20%
10.07%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 14.67
DGX's Operating Margin % is ranked higher than
82% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. DGX: 14.67 )
Ranked among companies with meaningful Operating Margin % only.
DGX' s Operating Margin % Range Over the Past 10 Years
Min: 13.22  Med: 14.89 Max: 18.23
Current: 14.67
13.22
18.23
Net Margin % 9.77
DGX's Net Margin % is ranked higher than
79% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. DGX: 9.77 )
Ranked among companies with meaningful Net Margin % only.
DGX' s Net Margin % Range Over the Past 10 Years
Min: 6.37  Med: 9.62 Max: 11.88
Current: 9.77
6.37
11.88
ROE % 14.26
DGX's ROE % is ranked higher than
85% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. DGX: 14.26 )
Ranked among companies with meaningful ROE % only.
DGX' s ROE % Range Over the Past 10 Years
Min: 12.11  Med: 15.09 Max: 20.86
Current: 14.26
12.11
20.86
ROA % 6.82
DGX's ROA % is ranked higher than
80% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. DGX: 6.82 )
Ranked among companies with meaningful ROA % only.
DGX' s ROA % Range Over the Past 10 Years
Min: 5.28  Med: 7 Max: 9.31
Current: 6.82
5.28
9.31
ROC (Joel Greenblatt) % 77.17
DGX's ROC (Joel Greenblatt) % is ranked higher than
92% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. DGX: 77.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DGX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 78.51  Med: 100.79 Max: 143.99
Current: 77.17
78.51
143.99
3-Year Revenue Growth Rate 1.60
DGX's 3-Year Revenue Growth Rate is ranked lower than
58% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. DGX: 1.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DGX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.6  Med: 7.15 Max: 15.4
Current: 1.6
1.6
15.4
3-Year EBITDA Growth Rate -1.90
DGX's 3-Year EBITDA Growth Rate is ranked lower than
58% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DGX: -1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DGX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.2 Max: 28.4
Current: -1.9
0
28.4
3-Year EPS without NRI Growth Rate 2.80
DGX's 3-Year EPS without NRI Growth Rate is ranked higher than
55% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. DGX: 2.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DGX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.4 Max: 61.5
Current: 2.8
0
61.5
GuruFocus has detected 3 Warning Signs with Quest Diagnostics Inc DGX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DGX's 30-Y Financials

Financials (Next Earnings Date: 2019-04-19)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2018

DGX Guru Trades in Q1 2018

Paul Tudor Jones 3,976 sh (New)
Chris Davis 133,375 sh (+0.51%)
Barrow, Hanley, Mewhinney & Strauss 1,871 sh (+144.26%)
Pioneer Investments 149,334 sh (+19.89%)
Ray Dalio 119,129 sh (+479.42%)
Bernard Horn 61,733 sh (unchged)
Steven Cohen Sold Out
Caxton Associates Sold Out
David Dreman 7,786 sh (-16.26%)
Joel Greenblatt 164,830 sh (-37.37%)
John Rogers 240,442 sh (-3.10%)
Murray Stahl 5,500 sh (-11.29%)
John Hussman 700 sh (-98.62%)
Jeremy Grantham 2,300 sh (-39.47%)
Jeff Auxier 40,420 sh (-5.11%)
Jim Simons 339,800 sh (-60.73%)
» More
Q2 2018

DGX Guru Trades in Q2 2018

Charles Brandes 1,839 sh (New)
John Rogers 243,599 sh (+1.31%)
Paul Tudor Jones 13,451 sh (+238.30%)
Pioneer Investments 183,814 sh (+23.09%)
Jeremy Grantham 2,300 sh (unchged)
Jeff Auxier 40,420 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Joel Greenblatt 2,624 sh (-98.41%)
Chris Davis 133,157 sh (-0.16%)
Murray Stahl 5,350 sh (-2.73%)
John Hussman 500 sh (-28.57%)
Barrow, Hanley, Mewhinney & Strauss 1,450 sh (-22.50%)
Ray Dalio 26,555 sh (-77.71%)
Jim Simons 251,500 sh (-25.99%)
» More
Q3 2018

DGX Guru Trades in Q3 2018

Charles Brandes 1,949 sh (+5.98%)
Ray Dalio 33,261 sh (+25.25%)
Jim Simons 259,400 sh (+3.14%)
John Rogers 260,261 sh (+6.84%)
Pioneer Investments 204,885 sh (+11.46%)
Joel Greenblatt 58,143 sh (+2115.82%)
Paul Tudor Jones 21,857 sh (+62.49%)
John Hussman 500 sh (unchged)
Bernard Horn 61,733 sh (unchged)
Jeremy Grantham 2,300 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss Sold Out
Chris Davis 132,539 sh (-0.46%)
Murray Stahl 5,300 sh (-0.93%)
Jeff Auxier 39,420 sh (-2.47%)
» More
Q4 2018

DGX Guru Trades in Q4 2018

Caxton Associates 4,680 sh (New)
Steven Cohen 150,000 sh (New)
John Hussman 800 sh (+60.00%)
Charles Brandes 5,479 sh (+181.12%)
Chris Davis 798,392 sh (+502.38%)
Ray Dalio 141,726 sh (+326.10%)
John Rogers 354,042 sh (+36.03%)
Joel Greenblatt 121,818 sh (+109.51%)
Jeremy Grantham Sold Out
Paul Tudor Jones Sold Out
Jim Simons 48,820 sh (-81.18%)
Jeff Auxier 39,270 sh (-0.38%)
Murray Stahl 5,250 sh (-0.94%)
Pioneer Investments 198,258 sh (-3.23%)
» More
» Details

Insider Trades

Latest Guru Trades with DGX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NAS:IDXX, NYSE:LH, XTER:SRT3, SZSE:300676, XPAR:BIM, XSWX:LONN, TSE:6869, XPAR:ERF, NYSE:PKI, NYSE:IQV, NYSE:BIO, NYSE:QGEN, NAS:DXCM, NYSE:A, NAS:ICLR, NAS:EXAS, XTER:AFX, NAS:PRAH, MIL:DIA, NYSE:CRL » details
Traded in other countries:QDI.Germany,
Headquarter Location:USA
Quest Diagnostics Inc provides diagnostic testing, information, and services, providing insights that enable patients and physicians to make healthcare decisions. It provides diagnostics for insurers and healthcare information technology businesses.

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates about 90% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing at its national network of 2,000 patient service centers. The firm also runs a diagnostic solutions segment which provides clinical trials testing, risk assessment services, and information technology solutions.

Guru Investment Theses on Quest Diagnostics Inc

Jeff Auxier Comments on Quest Diagnostics - Nov 08, 2018

Despite missing top line expectations, Quest Diagnostics (NYSE:DGX) has established a close partnership with UnitedHealth. They are now the in-network lab for all of UnitedHealthcare’s 48 million patients as well as collaborating with UnitedHealth on a variety of programs designed to increase standard of care while reducing costs.





From Jeff Auxier (Trades, Portfolio)'s third-quarter 2018 shareholder commentary.

Check out Jeff Auxier latest stock trades

Bernard Horn Comments on Quest Diagnostics - Jul 23, 2018

Quest Diagnostics (NYSE:DGX) faced headwinds after Medicare cut testing service rates. To counteract this government mandate, Quest expanded relationships with hospital systems and diversified via acquisitions. The company gained +10% in the quarter.



From Bernard Horn (Trades, Portfolio)'s Polaris Global Value Fund 2nd quarter 2018 shareholder letter.



Check out Bernard Horn latest stock trades

Bernard Horn Comments on Quest Diagnostics - Oct 18, 2017

Another health care sector holding, Quest Diagnostics (NYSE:DGX) reported solid quarterly revenues, attributable to their expanding book of business and healthy operating cash flow position. The company raised full-year guidance, confident in its business fundamentals and outlook. The stock price was stable until September 22, when the Centers for Medicare & Medicaid Services introduced proposed Medicare payment rates for clinical diagnostic laboratory tests. Draft rates called for a 10% rate cut in 2018 with heftier cuts from 2019-2021. Quest Diagnostics’ stock reacted negatively to this news and management intends to challenge the proposal.

From Bernard Horn (Trades, Portfolio)'s third quarter 2017 shareholder commentary.

Check out Bernard Horn latest stock trades

Top Ranked Articles about Quest Diagnostics Inc

Quest Diagnostics Names Gabrielle Wolfson Senior Vice President and Chief Information and Digital Officer
Quest Diagnostics Completes Acquisition of Laboratory Services Business of Boyce & Bynum Pathology Laboratories
Quest Diagnostics Named One of 2019 "World's Most Admired Companies" by Fortune Magazine for Fourth Consecutive Year
More Adults Know Their Multidigit Wi-Fi Password Than Vital Health Information, Including Their Single-Letter Blood Type
Quest Diagnostics To Release Fourth Quarter And Full Year 2018 Financial Results On February 14
Quest Diagnostics To Speak At The 37th Annual J.P. Morgan Healthcare Conference
Big Pharma Tapping Genetic Testing Companies for Data to Speed Drug Development GlaxoSmithKline deal with 23andMe could pave the way for other collaborations
With the market for direct-to-consumer medical testing forecast to explode, investors may want to take a close look at the leading publicly traded competitors, as well as private firms that could be potential IPOs or acquisition targets. Read more...
Quest Diagnostics Completes Sale of India Diagnostics Services Business to Strand Life Sciences
Workforce Drug Positivity Rises by Double-Digits in Almost One-Third of U.S. Industry Sectors Examined, According to New Quest Diagnostics Analysis
PAMA is Here, But Most Hospitals are Unaware of Its Impact, Study Finds

Ratios

vs
industry
vs
history
PE Ratio 16.60
DGX's PE Ratio is ranked higher than
76% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. DGX: 16.60 )
Ranked among companies with meaningful PE Ratio only.
DGX' s PE Ratio Range Over the Past 10 Years
Min: 9.09  Med: 16.87 Max: 27.48
Current: 16.6
9.09
27.48
Forward PE Ratio 13.26
DGX's Forward PE Ratio is ranked higher than
90% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. DGX: 13.26 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.60
DGX's PE Ratio without NRI is ranked higher than
77% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. DGX: 16.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
DGX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 9.48  Med: 15.49 Max: 22.81
Current: 16.6
9.48
22.81
Price-to-Owner-Earnings 15.26
DGX's Price-to-Owner-Earnings is ranked higher than
59% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. DGX: 15.26 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
DGX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.22  Med: 24.78 Max: 125.9
Current: 15.26
12.22
125.9
PB Ratio 2.27
DGX's PB Ratio is ranked higher than
66% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. DGX: 2.27 )
Ranked among companies with meaningful PB Ratio only.
DGX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 2.44 Max: 3.22
Current: 2.27
1.85
3.22
PS Ratio 1.61
DGX's PS Ratio is ranked higher than
72% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. DGX: 1.61 )
Ranked among companies with meaningful PS Ratio only.
DGX' s PS Ratio Range Over the Past 10 Years
Min: 1.04  Med: 1.35 Max: 2.1
Current: 1.61
1.04
2.1
Price-to-Free-Cash-Flow 14.90
DGX's Price-to-Free-Cash-Flow is ranked higher than
82% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. DGX: 14.90 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
DGX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.23  Med: 14.3 Max: 21.58
Current: 14.9
8.23
21.58
Price-to-Operating-Cash-Flow 10.14
DGX's Price-to-Operating-Cash-Flow is ranked higher than
79% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. DGX: 10.14 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
DGX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.98  Med: 10.92 Max: 14.26
Current: 10.14
6.98
14.26
EV-to-EBIT 14.12
DGX's EV-to-EBIT is ranked higher than
76% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. DGX: 14.12 )
Ranked among companies with meaningful EV-to-EBIT only.
DGX' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 10.7 Max: 17.1
Current: 14.12
5.9
17.1
EV-to-EBITDA 11.05
DGX's EV-to-EBITDA is ranked higher than
74% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. DGX: 11.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
DGX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 8.8 Max: 13.6
Current: 11.05
5
13.6
EV-to-Revenue 2.08
DGX's EV-to-Revenue is ranked higher than
72% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. DGX: 2.08 )
Ranked among companies with meaningful EV-to-Revenue only.
DGX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.1  Med: 1.8 Max: 2.6
Current: 2.08
1.1
2.6
Shiller PE Ratio 18.72
DGX's Shiller PE Ratio is ranked higher than
82% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. DGX: 18.72 )
Ranked among companies with meaningful Shiller PE Ratio only.
DGX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.47  Med: 20.05 Max: 29.86
Current: 18.72
14.47
29.86
Current Ratio 0.94
DGX's Current Ratio is ranked lower than
83% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. DGX: 0.94 )
Ranked among companies with meaningful Current Ratio only.
DGX' s Current Ratio Range Over the Past 10 Years
Min: 0.89  Med: 1.24 Max: 2.05
Current: 0.94
0.89
2.05
Quick Ratio 0.87
DGX's Quick Ratio is ranked lower than
77% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. DGX: 0.87 )
Ranked among companies with meaningful Quick Ratio only.
DGX' s Quick Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.17 Max: 1.93
Current: 0.87
0.82
1.93
Days Inventory 7.02
DGX's Days Inventory is ranked higher than
93% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. DGX: 7.02 )
Ranked among companies with meaningful Days Inventory only.
DGX' s Days Inventory Range Over the Past 10 Years
Min: 6.56  Med: 7.4 Max: 8.17
Current: 7.02
6.56
8.17
Days Sales Outstanding 49.05
DGX's Days Sales Outstanding is ranked higher than
75% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. DGX: 49.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
DGX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.51  Med: 43.82 Max: 49.05
Current: 49.05
40.51
49.05

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.31
DGX's Dividend Yield % is ranked higher than
74% of the 121 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.81 vs. DGX: 2.31 )
Ranked among companies with meaningful Dividend Yield % only.
DGX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.65  Med: 1.66 Max: 2.46
Current: 2.31
0.65
2.46
Dividend Payout Ratio 0.37
DGX's Dividend Payout Ratio is ranked higher than
60% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.32 vs. DGX: 0.37 )
Ranked among companies with meaningful Dividend Payout Ratio only.
DGX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.25 Max: 0.45
Current: 0.37
0.1
0.45
3-Year Dividend Growth Rate 9.90
DGX's 3-Year Dividend Growth Rate is ranked higher than
56% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.90 vs. DGX: 9.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
DGX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 6.95 Max: 55.4
Current: 9.9
0
55.4
Forward Dividend Yield % 2.41
DGX's Forward Dividend Yield % is ranked higher than
73% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. DGX: 2.41 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 5.58
DGX's 5-Year Yield-on-Cost % is ranked higher than
90% of the 142 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. DGX: 5.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
DGX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.57  Med: 4.01 Max: 5.94
Current: 5.58
1.57
5.94
3-Year Average Share Buyback Ratio 1.90
DGX's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. DGX: 1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DGX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -16.9  Med: 1.75 Max: 6.2
Current: 1.9
-16.9
6.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.12
DGX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
79% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. DGX: 1.12 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
DGX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.69  Med: 0.95 Max: 2.38
Current: 1.12
0.69
2.38
Price-to-Median-PS-Value 1.20
DGX's Price-to-Median-PS-Value is ranked lower than
69% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. DGX: 1.20 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DGX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 1.09 Max: 1.49
Current: 1.2
0.24
1.49
Earnings Yield (Greenblatt) % 7.08
DGX's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. DGX: 7.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DGX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 5.9  Med: 9.4 Max: 16.9
Current: 7.08
5.9
16.9
Forward Rate of Return (Yacktman) % 6.09
DGX's Forward Rate of Return (Yacktman) % is ranked lower than
53% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. DGX: 6.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
DGX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.4  Med: 13.5 Max: 20.6
Current: 6.09
4.4
20.6

More Statistics

Revenue (TTM) (Mil) $7,531.00
EPS (TTM) $ 5.29
Beta0.96
Volatility18.01%
52-Week Range $78.95 - 116.49
Shares Outstanding (Mil)135.00

Analyst Estimate

Dec19 Dec20
Revenue (Mil $) 7,729 7,945
EBIT (Mil $) 1,256 1,286
EBITDA (Mil $) 1,560 1,465
EPS ($) 5.89 6.31
EPS without NRI ($) 5.89 6.31
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.82%
Dividends per Share ($) 2.08 2.22

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}